Rivals Gain on Pfizer Drug Trial News
CNBC "On-Air Stocks" Editor
I noted on the air this afternoon that Pfizer , which was trading at about $20.20, dropped in a few minutes to about $19.50 on heavy volume.
The European League Against Rheumatism has posted a summary of a trial of Pfizer's rheumatoid arthritis drug Tofacitinib, indicating that four patients died.
Several other health care companies that have competing drugs rose on this news: YMI Biosciences , Abbott Laboratories , and Rigel , which is partnered with AstraZeneca .
- Deaths in Pfizer Arthritis Trial Hurt Shares
Bookmark CNBC Data Pages:
Want updates whenever a Trader Talk blog is filed? Follow me on Twitter: twitter.com/BobPisani.
Questions? Comments? firstname.lastname@example.org